Washington District of Columbia, District of Columbia

A Long-term Access Programme for Subjects With Severe Asthma

Peptide-coupled Red Blood Cells for the Treatment of Multiple Sclerosis

The RED4MS trial is designed as a combination of a phase Ib (part A) and a phase IIa (part B) study. Part A is an open-label, dose-escalation study, enrolling 9 RRMS patients in three ascending dose groups. The first patient (sentinel) in each dose group will receive one cycle of the therapy, while the remaining patients will receive two treatment cycles. Part B is a baseline-to-treatment, dose-blinded, randomized study and is designed to test the safety and efficacy of three different doses of CLS12311. During baseline phase, a total of 45 patients with active disease on magnetic resonance imaging (MRI) will be selected for the treatment phase and randomized in a 1:1:1 ratio into one of three dosing groups. Each patient will receive two cycles of therapy.

A Phase 2b Dose Finding Study of RMC-035 in Participants Undergoing Open-chest Cardiac Surgery

Ultrasound-guided Tru-cut Biopsy in Patients with Suspected Ovarian Cancer: Adequacy, Accuracy, Safety and Patient Assessment.

1. Current State of Knowledge Ovarian cancer remains the most lethal gynecologic malignancy, largely due to the lack of early detection and its presentation at a late stage1,2. In patients with ovarian cancer, the most important prognostic factor is the absence of macroscopic tumor at the end of surgery as well as the histological type3. For this purpose, adequate imaging before surgery, as well as histological knowledge of the tumor before the application of neoadjuvant chemotherapy is of great essence. Ultrasound-guided or CT-guided tru-cut biopsy in patients with advanced ovarian cancer has slowly become the preferred method of histological verification over the last decade in patients with suspected advanced ovarian cancer, with prof. Fischerová and her team being the pioneers in its use4,5. Our aim is to prospectively evaluate the role of ultrasound-guided tru-cut biopsy in the hands of an expert certified sonographer within a gynecological oncological center and with the material examined by a concrete expert in the gynecological oncological pathology field. The novelty in our approach so to say will lie in these three factors: prospective design, two expert sonographers, and one expert pathologist. This project will also be the first to include a patient experience survey after the procedure. Furthermore, with this project, we will be able to create a prospective database allowing for further work in the future. 2. Material Support for the Project The ultrasound examination will be performed on the GE Voluson E10 system located in the gynecological oncology center, tru-cut biopsy will be performed using a fast-gun automated biopsy system for sampling with 16-18 Gauge tru-cut needle and a G/16-30 cm core-cut biopsy needle. Histological examination will be performed in the state of art Fingerland department of pathology. 3. Project Objectives The goal of this project is to assess the adequacy of the material obtained from ultrasound-guided tru-cut biopsy for histopathological and immunohistochemical examination, compare for the accuracy of the histopathological diagnosis in samples with adequate material using the definitive surgical specimen as the reference standard while prospectively registering patient experience and complications after the procedure. 4. Methodology All patients suspected of gynecological malignancies are regularly examined in the gynecological oncology tumor board. Patients with suspicion of advanced ovarian cancer will be indicated by the oncologist team member for expert ultrasound and tru-cut biopsy, these patients will be consecutively screened into the study after acquiring informed consent, patients who refuse consent will be monitored outside the study database. All patients will undergo coagulation tests before, including the appropriate management of anticoagulation treatment 6. The target population will be 30-40 patients over a period of two years. Included patients will undergo expert ultrasound examination by two project members including both transabdominal and transvaginal examination using the International Ovarian Tumor Analysis (IOTA) and Morphological Uterus Sonographic Assessment (MUSA) terms. Before the tru-cut biopsy, a Doppler examination will be performed with the frequency set to define surrounding blood vessels. A 16-18 gauge tru-cut needle will be used. The transabdominal (freehand) or/and transvaginal (needle guide) approach to the biopsy will be performed by one project member using a 16-18 gauge tru-cut needle with the penetration depth set at 15-22mm. The biopsy will be repeated 2-3 times to acquire 2-3 samples for histopathological examination. Following the procedure, patients will be observed for two hours in an outpatient setting for bleeding or early complications. Minor or major complications will be reported if they occur using the modified Dindo classification. A simple pain assessment survey will be filled in by the patient before dismissal. The biopsy material will be fixed in formalin and sent to the expert pathologist team member, results will be available within 3-5 working days. During the follow-up visit, another pain assessment survey will be filled to show the chronic effect after tru-cut biopsy. The patient will be examined again by the tumor board and after definitive surgery, the definitive material will be sent to the same expert pathologist who will be blinded to the initial diagnosis allowing for a blind reference standard. All the data will be collected in three Excel databases and managed by three team members, one for histopathological information, one for ultrasound information, and one for safety and pain assessment. For statistics purposes, we will collect information on true positive, true negative, false positive, and false negative results. This will allow for the analysis of sensitivity, specificity, positive predictive value, and negative predictive value of the accuracy of ultrasound-guided tru-cut biopsy in patients with suspicion of ovarian cancer.

A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

Eligible subjects will be randomized (1:1) to receive investigational product (ABP 206 or nivolumab). All subjects will be treated until disease progression, unacceptable toxicity, or subject withdrawal of consent for a maximum of 24 months of treatment. The total duration of study participation for each subject will be approximately 26 months.

A Study to Assess Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Reduced Ejection Fraction (Cycle-1-REF)